Introduction
The prevalence of congenital heart disease (CHD) is between 8 and 10 children per 1000 live births. The average number of cardiovascular surgeries for CHD that are necessary in Brazil is of the order of 23,077 procedures per year, including newborn babies with CHD and cases requiring reoperations (1) . Pulmonary complications of postoperative pediatric cardiac surgery observed in the study of Felcar et al. where: atelectasis, pneumonia, pleural effusion, pneumothorax, chylothorax, pulmonary hypertension, pulmonary haemorrhage and diaphragmatic paralysis, whereas the first two aforementioned complications are the more common ones (2) . Atelectasis, defined as collapse of a certain region of the lung parenchyma (3) is the most common complication in the postoperative period of cardiac surgery (4) by worsening oxygenation, decreasing pulmonary compliance, leading to inhibition of cough and pulmonary clearance and may lead to respiratory failure and increase pulmonary vascular resistance. Heart surgeries associated with CPB have as adverse effect the increased capillary permeability that causes edema, which results in decreased lung compliance and gas exchange (6) , in addition to lead to airway obstruction, atelectasis, decreased functional residual capacity and, therefore, hypoxemia (5) . Pulmonary complications are the most common causes of morbidity and mortality in the postoperative period after congenital heart surgery. Both mechanical and gas exchange abnormalities result in increased ventilator requirements, intensive care unit (ICU) stay and mortality.
Parenchymal lung disease can be caused by a variety of conditions including nosocomial pneumonia, atelectasis and use of cardiopulmonary bypass. Direct surgical trauma to the respiratory system can result in diaphragmatic paralysis, chylothorax, subglottic stenosis or vocal cord paralysis. Disturbances in the pulmonary vasculature can also trigger complications including pulmonary embolism, plastic bronchitis and even pulmonary hypertensive crises in certain at risk populations (7).
Case
One year old female patient followed with tetralogy of fallot (TOF) was admitted to our service for surgical repair. Her weight was eight kilograms. She was diagnosed with TOF in utero by fetal echocardiography at 27 weeks of gestation. After birth her echocardiography and cardiac catheterization findings were intact Interatrial septum, sub aortic ventricular septal defect, dextroposed aorta, right ventricular hypertrophy, hypo-plastic pulmonary artery and dilated ascending aorta. Total correction of TOF was decided. VSD was repaired with a Dacron patch. The infundibular muscle was resected to allow for unobstructed flow of blood to the pulmonary valve and the area above the pulmonary valve was opened with a PTFE patch. On the first postoperative day when she met extubation criteria she was extubated. 6 hours after extubation she had difficulty in breathing. Her arterial blood gas was analysed. She had respiratory acidosis and she was re-entubated.
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Her chest x ray showed total atelectasis of the right lung. After 15 hours she was extubated again. We started to treat the patient with nebulised Dornase alpha (Pulmozyme®) twice a day. Pulmozyme is a recombinant human deoxyribonuclease I (rhDNase) an enzyme which selectively cleaves DNA. Each ampule has 2.5 mL of the solution. Each mL of aqueous solution contains 1 mg dornase alfa. After administration of 2.5 mg of Dornase alpha twice a day for three days the atelectasis of the right lung started to recover. The patient was discharged from the Intensive Care Unit (ICU) and was followed in the clinic. She was treated with Dornase alpha for three more days in the clinic and then on the fifth day she was discharged from the hospital.
Discussion
Atelectasis resolves with the use of noninvasive mechanical ventilation but after the extubation, by the effect of the spontaneous breathing, lung starts to collapse. Postoperative pain management is important in patients who undergo open heart surgery and aorta surgery. The use of opioid-based analgesics for pain control after cardiac surgery is inevitable. Poorly controlled pain also contributes to hemodynamic instability (8). In fact, several authors have reported that a continuous positive airway pressure, with or without intermittent positive pressure ventilation, alleviates a tracheal collapse (9, 10) .
Pulmozyme is a nebulised form of recombinant human DNase I (rhDNase). It is reliable, non-invasive and FDA approved. Recombinant human DNase I (rhDNase) has been shown to depolymerise DNA and thereby reduce the in vitro viscoelasticity of sputum in patients with cystic fibrosis and improved pulmonary function in patients with cystic fibrosis (CF) (11) .
Its efficacy has been well documented in cystic fibrosis, whereas case reports have described a beneficial effect in other respiratory disorders. Recombinant human DNase I (rhDNase, Pulmozyme, dornase alpha) has been approved for the management of CF (12, 13) .
Conclusion
In conclusion, nebulised form of Dornase Alpha (Pulmozyme®) has a positive effect on morbidity and mortality in patients with atelectasis that do not resolve due to pulmonary medication and rehabilitation program after congenital heart surgery
